Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (respiratory secretory cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: kd7040, tilarginine, gw-274150 +1 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 22 Parkinson's papers of 3,606 | 0.59 |
| pathways Reactome | 5 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2694
Sealed predictions
- NOS2 in dopamine neurons, braak-0.39 (p 0.300) → +0.17 (p 0.670)receipt 2702
Swarm cases
receipt 2702: NOS2 in dopamine neurons, braak
- power
- full sample -0.11 (p 0.652, n 18), 95% CI -0.55 to +0.37. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.10 (p 0.683, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.24 (p 0.337, n 18). could be the mix.
- skeptic
- leave-one-out range -0.24 to -0.00, sign flips 0; without severely affected donors -0.11 (p 0.652, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NOS2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts